Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Insights into the results and implications of the COMMANDS & IMerge studies in LR-MDS

Anand Patel • 6 Jun 2023
ASCO 2023
Myelodysplastic Syndromes Epoetin alfa ESA Imetelstat Luspatercept
COMMANDS IMerge

Anand Patel, MD, University of Chicago, Chicago, IL, discusses the implications of the COMMANDS (NCT03682536) and IMege (NCT02598661) Phase III trials in patients with lower-risk myelodysplastic syndromes (LR-MDS) with anemia, reflecting on the findings and questions that arise from these studies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anand Patel

4:22
Accelerated-phase MPNs: pathophysiology, treatment approaches and ongoing clinical trials
Anand Patel • 6 Jun 2023
4:36
COMMANDS: luspatercept versus epoetin alfa in LR-MDS-associated anemia - results & caveats
Anand Patel • 6 Jun 2023
2:41
The potential of targeting CD123 in myeloid malignancies
Anand Patel • 6 Jun 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals